

TABLE S3. Dataset including demographic and diseases features of the overall population, patients discontinuing and continuing treatment at different timepoints.

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
Gender						
n	251		1580		1831	
F	119	(47.4%)	713	(45.1%)	832	(45.4%)
M	132	(52.6%)	867	(54.9%)	999	(54.6%)
Smoking						
n	251		1578		1829	
Former smoker	20	(8.0%)	126	(8.0%)	146	(8.0%)
NO	172	(68.5%)	1087	(68.9%)	1259	(68.8%)
YES	59	(23.5%)	365	(23.1%)	424	(23.2%)
Asthma						
n	251		1579		1830	
NO	172	(68.5%)	1081	(68.5%)	1253	(68.5%)
YES	79	(31.5%)	498	(31.5%)	577	(31.5%)
Rhinitis						
n	251		1579		1830	
NO	133	(53.0%)	838	(53.1%)	971	(53.1%)

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
Rhinitis						
YES	118	(47.0%)	741	(46.9%)	859	(46.9%)
Conjunctivitis						
n	250		1579		1829	
NO	173	(69.2%)	1016	(64.3%)	1189	(65.0%)
YES	77	(30.8%)	563	(35.7%)	640	(35.0%)
Antihistamines						
n	251		1580		1831	
NO	182	(72.5%)	1209	(76.5%)	1391	(76.0%)
YES	69	(27.5%)	371	(23.5%)	440	(24.0%)
Cyclosporine						
n	251		1580		1831	
NO	204	(81.3%)	1491	(94.4%)	1695	(92.6%)
YES	47	(18.7%)	89	(5.6%)	136	(7.4%)
Azathioprine						
n	251		1580		1831	

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
Azathioprine						
NO	251	(100.0%)	1572	(99.5%)	1823	(99.6%)
YES	0		8	(0.5%)	8	(0.4%)
Methotrexate						
n	251		1580		1831	
NO	245	(97.6%)	1549	(98.0%)	1794	(98.0%)
YES	6	(2.4%)	31	(2.0%)	37	(2.0%)
Mycophenolate mofetil						
n	251		1580		1831	
NO	251	(100.0%)	1579	(99.9%)	1830	(99.9%)
YES	0		1	(0.1%)	1	(0.1%)
Systemic corticosteroids						
n	251		1580		1831	
NO	228	(90.8%)	1522	(96.3%)	1750	(95.6%)
YES	23	(9.2%)	58	(3.7%)	81	(4.4%)

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
Phototherapy						
n	251		1580		1831	
NO	191	(76.1%)	1560	(98.7%)	1751	(95.6%)
YES	60	(23.9%)	20	(1.3%)	80	(4.4%)
Dupilumab						
n	248		1576		1824	
NO	115	(46.4%)	172	(10.9%)	287	(15.7%)
YES	133	(53.6%)	1404	(89.1%)	1537	(84.3%)
Stopped therapy (any reason) at visit 1						
n	251		1580		1831	
NO	59	(23.5%)	1580	(100.0%)	1639	(89.5%)
YES	192	(76.5%)	0		192	(10.5%)
Stopped therapy (any reason) at visit 2						

n	236		1534		1770
NO	173 (73.3%)		1534 (100.0%)		1707 (96.4%)
YES	63 (26.7%)		0		63 (3.6%)

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831
Stopped therapy (any reason) at visit 3					
n	190		1434		1624
NO	162 (85.3%)		1434 (100.0%)		1596 (98.3%)
YES	28 (14.7%)		0		28 (1.7%)
Stopped therapy autonomously at visit 1					
n	192		58		250
NO	100 (52.1%)		58 (100.0%)		158 (63.2%)
YES	92 (47.9%)		0		92 (36.8%)
Stopped therapy autonomously at visit 2					
n	50		115		165
NO	36 (72.0%)		115 (100.0%)		151 (91.5%)
YES	14 (28.0%)		0		14 (8.5%)
Stopped therapy autonomously at visit 3					
n	48		146		194
NO	40 (83.3%)		146 (100.0%)		186 (95.9%)
YES	8 (16.7%)		0		8 (4.1%)

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831
Stopped therapy by general practitioner at visit 1					
n	184		58		242
NO	172 (93.5%)		58 (100.0%)		230 (95.0%)
YES	12 (6.5%)		0		12 (5.0%)
Stopped therapy by general practitioner at visit 2					
n	50		114		164
NO	47 (94.0%)		114 (100.0%)		161 (98.2%)
YES	3 (6.0%)		0		3 (1.8%)

Stopped therapy by general practitioner at visit 3				
n	48		117	165
NO	47 (97.9%)		117 (100.0%)	164 (99.4%)
YES	1 (2.1%)		0	1 (0.6%)
Stopped therapy by dermatologist at visit 1				
n	183		30	213
NO	142 (77.6%)		30 (100.0%)	172 (80.8%)
YES	41 (22.4%)		0	41 (19.2%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Stopped therapy by dermatologist at visit 2			
n	51	114	165
NO	29 (56.9%)	114 (100.0%)	143 (86.7%)
YES	22 (43.1%)	0	22 (13.3%)
Stopped therapy by dermatologist at visit 3			
n	48	116	164
NO	25 (52.1%)	116 (100.0%)	141 (86.0%)
YES	23 (47.9%)	0	23 (14.0%)
Reason stopped therapy at visit 1			
n	192	4	196
Other cause	101 (52.6%)	0	101 (51.5%)
Comorbidity	10 (5.2%)	0	10 (5.1%)
Contact with SARS-CoV-2+ subject	7 (3.6%)	0	7 (3.6%)
Age >60	6 (3.1%)	4 (100.0%)	10 (5.1%)
SARS-CoV-2 infection	6 (3.1%)	0	6 (3.1%)
Fear of SARS-CoV-2 infection	62 (32.3%)	0	62 (31.6%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Reason stopped therapy at visit 2			

n	49	0	49
Other cause	32 (65.3%)	0	32 (65.3%)
Comorbidity	5 (10.2%)	0	5 (10.2%)
Age >60	3 (6.1%)	0	3 (6.1%)
SARS-CoV-2 infection	3 (6.1%)	0	3 (6.1%)
Fear of SARS-CoV-2 infection	6 (12.2%)	0	6 (12.2%)
Reason stopped therapy at visit 3			
n	48	0	48
Other cause	35 (72.9%)	0	35 (72.9%)
Comorbidity	2 (4.2%)	0	2 (4.2%)
Age >60	6 (12.5%)	0	6 (12.5%)
SARS-CoV-2 infection	2 (4.2%)	0	2 (4.2%)
Fear of SARS-CoV-2 infection	3 (6.3%)	0	3 (6.3%)
COVID-19 infection at visit 1			
n	247	1469	1716

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
COVID-19 infection at visit 1			
NO	241 (97.6%)	1462 (99.5%)	1703 (99.2%)
YES	6 (2.4%)	7 (0.5%)	13 (0.8%)
COVID-19 infection at visit 2			
n	240	1536	1776
NO	236 (98.3%)	1535 (99.9%)	1771 (99.7%)
YES	4 (1.7%)	1 (0.1%)	5 (0.3%)
COVID-19 infection at visit 3			
n	225	1469	1694
NO	223 (99.1%)	1469 (100.0%)	1692 (99.9%)
YES	2 (0.9%)	0	2 (0.1%)
Buffer performed at visit 1			
n	247	1469	1716
NO	228 (92.3%)	1446 (98.4%)	1674 (97.6%)
YES	19 (7.7%)	23 (1.6%)	42 (2.4%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Buffer performed at visit 2			
n	240	1535	1775
NO	230 (95.8%)	1525 (99.3%)	1755 (98.9%)
YES	10 (4.2%)	10 (0.7%)	20 (1.1%)
Buffer performed at visit 3			
n	225	1469	1694
NO	220 (97.8%)	1457 (99.2%)	1677 (99.0%)
YES	5 (2.2%)	12 (0.8%)	17 (1.0%)
Hospitalisation at visit 1			
n	246	1449	1695
NO	244 (99.2%)	1448 (99.9%)	1692 (99.8%)
YES	2 (0.8%)	1 (0.1%)	3 (0.2%)
Hospitalisation at visit 2			
n	240	1536	1776
NO	240 (100.0%)	1536 (100.0%)	1776 (100.0%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Hospitalisation at visit 3			
n	225	1469	1694
NO	225 (100.0%)	1469 (100.0%)	1694 (100.0%)
Dosage changed or lengthening of time intervals at visit 1			
n	231	1479	1710
NO	214 (92.6%)	1463 (98.9%)	1677 (98.1%)
YES	17 (7.4%)	16 (1.1%)	33 (1.9%)
Dosage changed or lengthening of time intervals at visit 2			
n	146	1096	1242
NO	136 (93.2%)	1086 (99.1%)	1222 (98.4%)
YES	10 (6.8%)	10 (0.9%)	20 (1.6%)
Dosage changed or lengthening of time intervals at visit 3			
n	148	906	1054
NO	139 (93.9%)	902 (99.6%)	1041 (98.8%)
YES	9 (6.1%)	4 (0.4%)	13 (1.2%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Modified therapy at visit 2			
n	240	1535	1775
NO	161 (67.1%)	1449 (94.4%)	1610 (90.7%)
YES	79 (32.9%)	86 (5.6%)	165 (9.3%)
Modified therapy at visit 3			
n	224	1437	1661
NO	160 (71.4%)	1393 (96.9%)	1553 (93.5%)
YES	64 (28.6%)	44 (3.1%)	108 (6.5%)
Other therapy at visit 1			
n	250	1399	1649
NO	71 (28.4%)	446 (31.9%)	517 (31.4%)
Topical therapy	109 (43.6%)	275 (19.7%)	384 (23.3%)
Homeopathy	0	3 (0.2%)	3 (0.2%)
Emollients	70 (28.0%)	675 (48.2%)	745 (45.2%)
Other therapy at visit 2			
n	183	1227	1410

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Other therapy at visit 2			
NO	38 (20.8%)	261 (21.3%)	299 (21.2%)
Topical therapy	52 (28.4%)	212 (17.3%)	264 (18.7%)
Homeopathy	1 (0.5%)	2 (0.2%)	3 (0.2%)
Emollients	91 (49.7%)	748 (61.0%)	839 (59.5%)
Other therapy at visit 3			
n	180	1232	1412
NO	43 (23.9%)	341 (27.7%)	384 (27.2%)
Topical therapy	53 (29.4%)	217 (17.6%)	270 (19.1%)
Homeopathy	1 (0.6%)	3 (0.2%)	4 (0.3%)
Emollients	82 (45.6%)	668 (54.2%)	750 (53.1%)
Therapies followed during the study			
n	251	1580	1831
Anti-histamines	2 (0.8%)	36 (2.3%)	38 (2.1%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Therapies followed during the study			
Anti-histamines	0	3 (0.2%)	3 (0.2%)
Azathioprine			
Anti-histamines Cyclosporine	16 (6.4%)	35 (2.2%)	51 (2.8%)
Anti-histamines Cyclosporine Systemic corticosteroids	3 (1.2%)	2 (0.1%)	5 (0.3%)
Anti-histamines Cyclosporine Systemic cortico. Dupilumab	1 (0.4%)	1 (0.1%)	2 (0.1%)
Anti-histamines Cyclosporine Systemic corticosteroids phototherapy	1 (0.4%)	0	1 (0.1%)
Anti-histamines Cyclosporine Dupilumab	4 (1.6%)	11 (0.7%)	15 (0.8%)
Anti-histamines Cyclosporine Methotrexate Dupilumab	0	1 (0.1%)	1 (0.1%)
Anti-histamines Systemic corticosteroids	9 (3.6%)	9 (0.6%)	18 (1.0%)
Anti-histamines Systemic corticoster. Dupilumab	6 (2.4%)	34 (2.2%)	40 (2.2%)
Anti-histamines Dupilumab	32 (12.7%)	322 (20.4%)	354 (19.3%)
Anti-histamines Phototherapy	15 (6.0%)	3 (0.2%)	18 (1.0%)
Anti-histamines Phototherapy Dupilumab	6 (2.4%)	3 (0.2%)	9 (0.5%)
Anti-histamines Methotrexate	0	3 (0.2%)	3 (0.2%)
Anti-histamines Methotrexate Systemic corticosteroids	1 (0.4%)	1 (0.1%)	2 (0.1%)
Anti-histamines Methotrexate Systemic corticosteroids Dupilumab	0	1 (0.1%)	1 (0.1%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Therapies followed during the study			
Anti-histamines Methotrexate Dupilumab	0	6 (0.4%)	6 (0.3%)
Anti-histamines Mycophen. mofetil Systemic cortic. Dupi.	0	1 (0.1%)	1 (0.1%)
Azathioprine	0	5 (0.3%)	5 (0.3%)
Cyclosporine	10 (4.0%)	37 (2.3%)	47 (2.6%)
Cyclosporine Systemic corticoster. Dupilumab	1 (0.4%)	3 (0.2%)	4 (0.2%)
Cyclosporine Systemic corticoster. Phototherapy	1 (0.4%)	0	1 (0.1%)
Cyclosporine Systemic corticoster. Phototherapy Dupilumab	0	1 (0.1%)	1 (0.1%)
Cyclosporine Dupilumab	12 (4.8%)	34 (2.2%)	46 (2.5%)
Cyclosporine Phototherapy	1 (0.4%)	0	1 (0.1%)
Cyclosporine Phototherapy Dupilumab	0	1 (0.1%)	1 (0.1%)
Cyclosporine Methotrexate	2 (0.8%)	2 (0.1%)	4 (0.2%)
Cyclosporine Methotrexate Dupilumab	0	1 (0.1%)	1 (0.1%)
Systemic corticoster.	4 (1.6%)	3 (0.2%)	7 (0.4%)
Systemic corticoster. Dupilumab	6 (2.4%)	46 (2.9%)	52 (2.8%)
Systemic corticoster. Phototherapy	0	3 (0.2%)	3 (0.2%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Therapies followed during the study			
Systemic corticoster. Photother Dupilumab	1 (0.4%)	1 (0.1%)	2 (0.1%)
Dupilumab	75 (29.9%)	938 (59.4%)	1013 (55.3%)
Phototherapy	28 (11.2%)	2 (0.1%)	30 (1.6%)
Photother Dupilumab	6 (2.4%)	6 (0.4%)	12 (0.7%)
Methotrexate	1 (0.4%)	16 (1.0%)	17 (0.9%)
Methotrexate Systemic corticoster. Dupilumab	0	4 (0.3%)	4 (0.2%)

Dupilumab Methotrexate	6 (2.4%)	3 (0.2%)	9 (0.5%)
Methotrexate Phototherapy	1 (0.4%)	0	1 (0.1%)
Methotrexate Phototherapy Dupilumab	0	1 (0.1%)	1 (0.1%)
Mycophen. mofetil Systemic cortic. Dupi.	0	1 (0.1%)	1 (0.1%)
Quarantene at vist 1			
n	247	1469	1716
NO	222 (89.9%)	1446 (98.4%)	1668 (97.2%)
YES	25 (10.1%)	23 (1.6%)	48 (2.8%)

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
Quarantene at vist 2			
n	240	1536	1776
NO	235 (97.9%)	1533 (99.8%)	1768 (99.5%)
YES	5 (2.1%)	3 (0.2%)	8 (0.5%)
Quarantene at vist 3			
n	225	1469	1694
NO	224 (99.6%)	1468 (99.9%)	1692 (99.9%)
YES	1 (0.4%)	1 (0.1%)	2 (0.1%)
Therapy restarted at vist 1			
n	182	1	183
NO	163 (89.6%)	1 (100.0%)	164 (89.6%)
YES	19 (10.4%)	0	19 (10.4%)
Therapy restarted at vist 2			
n	158	3	161
NO	96 (60.8%)	1 (33.3%)	97 (60.2%)
YES	62 (39.2%)	2 (66.7%)	64 (39.8%)

Patients discontinuing treatment	Patients continuing treatment	TOTAL
-------------------------------------	----------------------------------	-------

	N=251	N=1580	N=1831
Therapy restarted at vist 3			
n	70	3	73
NO	43 (61.4%)	3 (100.0%)	46 (63.0%)
YES	27 (38.6%)	0	27 (37.0%)
AD status at vist 1			
n	251	1577	1828
improved	39 (15.5%)	454 (28.8%)	493 (27.0%)
worsened	90 (35.9%)	162 (10.3%)	252 (13.8%)
stable	122 (48.6%)	961 (60.9%)	1083 (59.2%)
AD status at vist 2			
n	240	1535	1775
improved	53 (22.1%)	417 (27.2%)	470 (26.5%)
worsened	85 (35.4%)	138 (9.0%)	223 (12.6%)
stable	102 (42.5%)	980 (63.8%)	1082 (61.0%)
AD status at vist 3			
n	225	1464	1689

	Patients discontinuing treatment N=251	Patients continuing treatment N=1580	TOTAL N=1831
AD status at vist 3			
0.8	0	1 (0.1%)	1 (0.1%)
improved	69 (30.7%)	442 (30.2%)	511 (30.3%)
worsened	43 (19.1%)	101 (6.9%)	144 (8.5%)
stable	113 (50.2%)	920 (62.8%)	1033 (61.2%)
Age (years)			
n	251	1580	1831
Mean (SD)	41.5 (18.2)	42.3 (17.2)	42.2 (17.4)
Median	36.0	41.0	40.0
Range	17 ; 89	15 ; 92	15 ; 92
EASI at visit 1			
n	251	1580	1831
Mean (SD)	8.231 (7.457)	6.628 (7.773)	6.847 (7.748)
Median	5.600	4.000	4.000
Range	0.00 ; 32.00	0.00 ; 47.00	0.00 ; 47.00

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
EASI at visit 3						
n	91		655		746	
Mean (SD)	7.28 (7.68)		2.83 (3.43)		3.37 (4.42)	
Median	4.00		2.00		2.00	
Range	0.0 ; 33.0		0.0 ; 31.0		0.0 ; 33.0	
Change in EASI from visit 1 to visit 3						
n	91		655		746	
Mean (SD)	-0.230 (7.665)		-2.823 (7.103)		-2.507 (7.219)	
Median	-0.600		-1.000		-1.000	
Range	-26.00 ; 22.00		-47.00 ; 26.00		-47.00 ; 26.00	
P-value (for pre-post) Paired t-test					<0.0001	
VAS - pruritus at visit 1						
n	251		1577		1828	
Mean (SD)	3.7 (2.3)		2.4 (2.1)		2.6 (2.2)	
Median	4.0		2.0		2.0	
Range	0 ; 9		0 ; 10		0 ; 10	

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
VAS - pruritus at visit 2						
n	240		1535		1775	
Mean (SD)	3.8 (2.7)		2.2 (2.1)		2.5 (2.3)	
Median	4.0		2.0		2.0	
Range	0 ; 10		0 ; 10		0 ; 10	
VAS - pruritus at visit 3						
n	225		1465		1690	
Mean (SD)	3.3 (2.6)		2.0 (2.0)		2.2 (2.1)	
Median	3.0		2.0		2.0	
Range	0 ; 10		0 ; 10		0 ; 10	
Change in VAS - pruritus from visit 1 to visit 3						
n	225		1462		1687	
Mean (SD)	-0.2 (2.7)		-0.3 (2.0)		-0.3 (2.1)	
Median	0.0		0.0		0.0	
Range	-7 ; 10		-9 ; 8		-9 ; 10	
P-value (for pre-post) Paired t-test					<0.0001	

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
VAS - sleep at visit 1						
n	251		1577		1828	
Mean (SD)	2.7	(2.4)	1.6	(2.0)	1.7	(2.1)
Median	2.0		1.0		1.0	
Range	0	; 9	0	; 10	0	; 10
VAS - sleep at visit 2						
n	240		1535		1775	
Mean (SD)	2.8	(2.8)	1.5	(1.8)	1.6	(2.0)
Median	2.0		1.0		1.0	
Range	0	; 10	0	; 10	0	; 10
VAS - sleep at visit 3						
n	225		1465		1690	
Mean (SD)	2.2	(2.4)	1.2	(1.7)	1.3	(1.9)
Median	1.0		0.0		1.0	
Range	0	; 9	0	; 9	0	; 9

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
Change in VAS - sleep from visit 1 to visit 3						
n	225		1462		1687	
Mean (SD)	-0.3	(2.8)	-0.3	(1.9)	-0.3	(2.0)
Median	0.0		0.0		0.0	
Range	-8	; 8	-10	; 9	-10	; 9
P-value (for pre-post) Paired t-test					<0.0001	
VAS - skin damage at visit 1						
n	251		1577		1828	
Mean (SD)	3.5	(2.2)	2.3	(2.0)	2.5	(2.1)
Median	4.0		2.0		2.0	
Range	0	; 9	0	; 10	0	; 10
VAS - skin damage at visit 2						
n	240		1535		1775	
Mean (SD)	3.7	(2.6)	2.1	(1.9)	2.3	(2.1)
Median	3.0		2.0		2.0	
Range	0	; 10	0	; 10	0	; 10

	Patients discontinuing treatment N=251		Patients continuing treatment N=1580		TOTAL N=1831	
VAS - skin damage at visit 3						
n	225		1464		1689	
Mean (SD)	3.0	(2.4)	1.9	(1.9)	2.1	(2.0)
Median	2.0		2.0		2.0	
Range	0	; 9	0	; 9	0	; 9
Duration of total therapy interruption (days)						
n	98		0		98	
Mean (SD)	56.5	(27.2)			56.5	(27.2)
Median	56.0				56.0	
Range	0	; 125			0	; 125